Clinical Outcomes of CyberKnife Radiotherapy in Prostate Cancer Patients: Short-term, Single-Center Experience
고동훈, 김진범, 김형준, 김홍욱, 장영섭,
소속 상세정보
고동훈 ( Koh Dong-Hoon )
Konyang University College of Medicine Department of Urology
김진범 ( Kim Jin-Bum )
Konyang University College of Medicine Department of Urology
김형준 ( Kim Hyung-Joon )
Konyang University College of Medicine Department of Urology
김홍욱 ( Kim Hong-Wook )
Konyang University College of Medicine Department of Urology
장영섭 ( Chang Young-Seop )
Konyang University College of Medicine Department of Urology
KMID : 0358320140550030172
Abstract
Purpose: In this retrospective study, we analyzed the outcomes of prostate cancer patients treated with the CyberKnife radiotherapy system (Accuray).
Materials and Methods: Between 2007 and 2010, 31 patients were treated for prostate cancer by use of the CyberKnife radiotherapy system. After excluding six patients who were lost to follow-up, data for the remaining 25 patients were analyzed. Patients were divided into the CyberKnife monotherapy group and a postexternal beam radiotherapy boost group. Clinicopathologic features and treatment outcomes were compared between the groups. The primary endpoint was biochemical recurrence-free survival period based on the Phoenix definition. Toxicities were evaluated by using the Radiation Therapy Oncology Group scoring criteria.
Results: Of 25 patients, 17 (68%) and 8 (32%) were classified in the monotherapy and boost groups, respectively. With a median follow-up of 29.3 months, most of the toxicities were grade 1 or 2 except for one patient in the boost group who experienced late grade 3 gastrointestinal toxicity. The overall biochemical recurrence rate was 20% (5/25) and the median time to biochemical recurrence was 51.9 months. None of the patients with low or intermediate risk had experienced biochemical recurrence during follow-up. Among D’Amico high-risk populations, 16.7% (1/6) in the monotherapy group and 50.0% (4/8) in the boost group experienced biochemical recurrence.
Conclusions: Our data support that prostate cancer treatment by use of the CyberKnife radiotherapy system is feasible. The procedure can be a viable option for managing prostate cancer either in a monotherapy setting or as a boost after conventional radiotherapy regardless of the patient’s risk stratification.
키워드
Prostate cancer; Recurrence; Stereotactic radiosurgery; Toxicity
원문 및 링크아웃 정보
등재저널 정보